期刊文献+

血栓弹力图法与光学比浊法评价急性冠状动脉综合征患者氯吡格雷反应性的临床研究 被引量:9

A comparison of thromboelastogram and light transmission aggregometry in detecting antiplatelet function of clopidogrel in patients with acute coronary syndrome
下载PDF
导出
摘要 目的获得急性冠状动脉综合征(ACS)患者氯吡格雷用药后血小板高反应性(HPR)发生率,比较血栓弹力图(TEG)和光学比浊法(LTA)检测血小板聚集功能的相关性。方法连续入选141例年龄≤80岁的ACS患者,服用氯吡格雷≥3 d后,采用TEG法和LTA法同时检测腺苷二磷酸(ADP)诱导的血小板聚集功能,将TEG法检测出的氯吡格雷抑制率〈30%或LTA法检测出最大血小板聚集率MPAR≥46%定义为HPR,比较两种方法检测结果的相关性。所有患者随访1个月,比较两种方法检测出的血小板反应预测临床不良事件的敏感性。结果采用TEG法检测出HPR患者49例(34.8%,49/141),LTA法检测出HPR 83例(58.9%,83/141),两者间比较,差异有统计学意义(χ^2=16.464,P=0.000)。TEG法检测出的HPR患者总临床缺血事件发生率(10.2%,5/49)有高于同法检测的非HPR患者(5.4%,5/92)的趋势,但两者间比较差异无统计学意义(OR 1.98,95%CI0.54-7.20,P=0.480)。LTA法检测出的HPR患者总临床缺血事件发生率6.0%(5/83),与非HPR患者8.6%(5/58)比较,差异无统计学意义(OR 0.68,95%CI 0.19-2.50,P=0.797)。结论 TEG法和LTA法检测ACS患者氯吡格雷反应性相关性较差,HPR检出率有显著差异。TEG法检测出的HPR患者出院后1个月的临床缺血事件发生率有高于非HPR患者的趋势。 Objective To obtain the incidence of high platelet reaction( HPR) in ACS patients treated with clopidogrel and to analyse the correlation between the testing results of thromboelastogram( TEG) and light transmission aggregometry( LTA). Methods A total of 141 ACS patients( all age≤80years old) who had taken clopidogrel at least for 3 days were enrolled in the study. All patients were given platelet function detection by means of TEG and LTA. High on-treatment platelet reactivity( HPR) was defined as 5 μmol / L ADP induced maximal platelet aggregation( MPAR) ≥46% in LTA and 2 μmol / L induced clopidogrel inhibition ratio 〈30% in TEG. Compare the correlation between results of the two assays and the sensitivity of HPRs measured by the two different assays in predicting adverse clinical events according to 1-month followed-up results. Results HPR was found in 49( 34. 8%) patients by TEG and in83( 58. 8%) patients by LTA and the difference between the two HPR ratio was significant( χ^2= 16. 464,P= 0. 000). The incidence of clinical ischemic events in TEG-HPR group was higher than that in non TEGHPR group( 10. 2% vs. 5. 4%,OR 1. 98,95% CI 0. 54-7. 20,P = 0. 480),but the difference was not significant( P〉 0. 05). There was no significant difference in the incidence of clinical ischemic events between LTA-HPR group and non LTA-HPR group( 6. 0% vs. 8. 6%,OR 0. 68,95% CI 0. 19-2. 50,P =0. 797). Conclusions The correlation between the testing results of TEG and LTA in ACS patients treated with clopidogrel was poor,HPR ratios detected by two assays were significantly different. The occurrence tendency of clinical ischemic events in TEG-HPR group was higher than that in non TEG-HPR group.
出处 《中国介入心脏病学杂志》 2015年第1期22-26,共5页 Chinese Journal of Interventional Cardiology
基金 北京市教育委员会青年英才计划(YETP0064)
关键词 氯吡格雷 血小板聚集 光学比浊法 血栓弹力图 急性冠状动脉综合征 Clopidogrel Platelet aggregation Thromboelastogram Light transmission aggregometry Acute coronary syndrome
  • 相关文献

参考文献14

  • 1Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/ AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 2011,124 :e574-e651.
  • 2Guthikonda S,Lev EI, Eikleiman NS. Resistance to aniplatelet therapy. Curr Cardiol Rep, 2005, 17 : 242- 248.
  • 3Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J, 2006,27 : 2420-2425.
  • 4Morneau KM, Reaves AB, Martin JB, et al. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplate|et therapy with aspirin and clopidogrel. J Manag Care Pharm, 2014, 20:187-193.
  • 5Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol, 2007,50 : 1822-1834.
  • 6Siller- Matula JM, Francesconi M, Dechant C, et al. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study, Int J Cardiol,2013,167:2018-2023.
  • 7Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007,28: 1598-1660.
  • 8急性冠状动脉综合征非血运重建患者的抗血小板治疗的中国专家共识组.急性冠状动脉综合征非血运重建患者的抗血小板治疗的中国专家共识(修订案).中国医刊,2011,46:79-85.
  • 9Angiolillo DJ,Suryadevara S, Capranzano P, et al. Antip|atelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. Catheter Cardiovasc Interv, 2009,73 : 1-14.
  • 10Breet NJ,van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 2010,303:754 - 762.

二级参考文献7

共引文献11

同被引文献59

  • 1李静,颜彦,吕迁洲.抑制血小板聚集药物的抵抗[J].中国药师,2007,10(1):66-68. 被引量:2
  • 2Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revaseularization [ J ]. Rev Esp Cardiol ( Engl Ed ), 2015,68(2) :144.
  • 3Brar SS,Ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention : A eollabora- tire meta-analysis of individual patieipant data [ J ]. JAMA, 2011,58 (19) :1945-1954.
  • 4Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium [ J ]. Circulation, 2011,123 ( 23 ) : 2736-2747.
  • 5Gurbel PA,Tantry US. Do platelet function testing and genotyping im- prove outcome in patients treated with antithrombotie agents? : platelet function testing and genotyping improve outcome in patients treated with antithrombotie agents [ J ]. Circulation, 2012, 125 ( 10 ) : 1276- 1287.
  • 6Aradi D, Storey RF, Komocsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention[ J] Eur Heart J,2014,35(4) :209-215.
  • 7Vadasz D, Sztriha LK, Sas K, et al. Aspirin and clopidogrel resist- ance:possible mechanisms and clinical relevance. Part II:Potential causes and laboratm'y tests [ J ]. IdeggyogySz, 2013,66 ( 1-2 ) : 15 -22.
  • 8Sambu N, Adharishnan A, Dent H, et al. Personalised anti-platelet therapy in stent thrombosis:observations from the clopidogrel resist- ance in stent thrombosis (CREST) registry [ J ]. Heart, 2012,98 ( 9 ) : 706-711.
  • 9Godschalk TC, Hackeng CM, ten Berg JM. Towards Personalized Medicine Based on Platelet Function Testing for Stent Thrombosis Patients [ J ]. Thrombosis, 2012,2012 ( 12 ) : 617098.
  • 10Gurbel PA, Bilden KP, Navickas IA, et al. Adenosine Diphosphate-in- duced platelet-fibrin clot strength:A new thrombelastographic indica- tor of long-term post-stenting ischemic events [ J ]. Am Heart J,2010, 160(2) :346-354.

引证文献9

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部